Trade Names:Didronel- Tablets 200 mg- Tablets 400 mgCO Etidronate (Canada)Gen-Etidronate (Canada)
Inhibits normal and abnormal bone resorption; reduces bone formation.
Approximately 3% is absorbed.
Approximately 50% of the absorbed dose is distributed to bone compartments. Does not cross blood-brain barrier.
The t ½ is 1 to 6 h. In animals, bone Cl is 165 days. Unabsorbed drug excreted in feces. Approximately 50% of the absorbed dose is excreted in the urine within 24 h.
Treatment of symptomatic Paget disease; prevention and treatment of heterotopic ossification following total hip replacement or caused by spinal cord injury.
Treatment of corticosteroid-induced osteoporosis.
Hypersensitivity to bisphosphonates; clinically overt osteomalacia.
PO Initial treatment is 5 to 10 mg/kg/day (not to exceed 6 mo) or 11 to 20 mg/kg/day (not to exceed 3 mo). Reserve doses greater than 10 mg/kg/day for specific situations. For retreatment, initiate only after etidronate-free period of at least 90 days and if there is evidence of active disease.Heterotopic Ossification from Spinal Cord InjuryAdults
PO 20 mg/kg/day for 2 wk followed by 10 mg/kg/day for 10 wk; total treatment period is 12 wk.Heterotopic Ossification Complicating Total Hip ReplacementAdults
PO 20 mg/kg/day for 1 mo preoperatively followed by 20 mg/kg/day for 3 mo postoperatively.
Store tablets away from excessive heat (less than 104°F).
Decreased etidronate absorption.Food
Absorption of etidronate is decreased by food.
None well documented.
Amnesia, confusion, depression, hallucination, headache, paresthesias (postmarketing).
Alopecia, Stevens-Johnson syndrome (postmarketing).
Diarrhea; nausea; diarrhea in enterocolitis patients; esophagitis, gastritis, glossitis, exacerbation of peptic ulcer disease, perforation of peptic ulcer (postmarketing).
Abnormal elevations of serum creatinine; mild to moderate abnormalities in renal function.
Agranulocytosis, pancytopenia, leukopenia (postmarketing).
Arthropathies including arthralgia and arthritis, bone fracture, leg cramps, osteomalacia (postmarketing).
Exacerbation of asthma (postmarketing).
Hypersensitivity (eg, angioedema, urticaria, rash, pruritus); increased or recurrent bone pain in Paget disease; hypocalcemia; nephrotic syndrome and fractures with excessive doses; hyperphosphatemia.
Document dates of previous treatment with etidronate.
Category C .
Safety and efficacy not established.
Etidronate suppresses bone turnover and may retard mineralization of osteoid laid down during bone accretion process.
Ensure that patient's daily calcium and vitamin D intake are evaluated before starting therapy and that calcium and/or vitamin D supplementation is being used in patient with inadequate daily intake.
Use this drug with caution in patients with active upper GI problems such as dysphagia (difficulty swallowing); symptomatic esophageal diseases; gastritis; duodenitis or ulcers.
Response may be slow and may continue for months after treatment has been discontinued. Dosage must not be prematurely increased or treatment prematurely reinitiated until patient has had at least 90-day etidronate-free interval.
Decrease etidronate dosage.
Diarrhea, vomiting, hypocalcemia.
Copyright © 2009 Wolters Kluwer Health.